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Highlights 
 In 42 first-episode psychosis patients, C-reactive protein and metabolic variables were 
combined in 3 metabolic factors. 
 Symptoms severity and treatment response were measured at 1-year follow-up. 
 Factor 1, accounting for baseline C-reactive protein, BMI and triglycerides, predicted 
symptoms severity and treatment response at 1-year follow-up. 
 The inflammatory-metabolic status at the onset of psychosis may be a predictor of clinical 
outcome.  
 
 
Abstract 
Background: Metabolic abnormalities and peripheral inflammation have been increasingly reported 
in patients at the onset of psychosis and associated with important physical health disorders and 
increased mortality. However, the impact of an abnormal metabolic-inflammatory status on the 
psychiatric outcome of these patients has not yet been investigated. 
Objectives: The aims of this study were 1) to explore whether, in a sample of patients at their first 
episode of psychosis (FEP), an overall metabolic-inflammatory status may be measured, by 
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combining metabolic and inflammatory variables in metabolic-inflammatory factors; 2) to explore the 
association between these factors and clinical outcome at 1-year follow-up (FU), in terms of 
symptoms severity and treatment response. 
Methods: In this longitudinal study we recruited 42 FEP patients and 46 healthy controls (HC) 
matched with patients for age, gender and ethnicity. At baseline (T1) we measured high sensitivity 
C-reactive protein (hsCRP) as biomarker of inflammation, and body mass index (BMI), lipid profile 
and gluco-metabolic parameters (glycated hemoglobin (HbA1c) and fasting glucose) as metabolic 
variables. A principal component analysis (PCA) was then used to reduce the dimensionality of the 
dataset accounting for both inflammation and metabolic status. In FEP patients, we assessed 
symptoms severity at T1 and at 1-year FU (T2) as well as treatment response to antipsychotics at 
T2. 
Results: at T1, FEP showed higher HbA1c (p=0.034), triglycerides (TG) (p=0.045) and BMI 
(p=0.026) than HC. PCA identified 3 factors: factor 1 accounting for hsCRP, TG and BMI, factor 2 
accounting for LDL and cholesterol, and factor 3 accounting for fasting glucose and HbA1c. Factor 
1 was associated with T1 negative symptoms severity (p=0.021) and predicted T2 positive (p=0.004) 
and overall symptoms severity (0.001), as well as general psychopathology (p<0.001) and T2 
treatment response (p=0.007). 
Conclusion: In this sample of FEP patients, inflammation and metabolism, closely correlated at the 
onset of psychosis, proved to play a key role as predictors of the clinical course of psychosis when 
combined in a single factor. These findings offer an important potential target for early screening and 
interventions. 
 
 
 
Keywords: inflammation, metabolism, predictor, first episode psychosis, clinical outcome, 
BMI. 
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      1. Introduction 
 
Metabolic abnormalities and peripheral inflammation have been increasingly reported in patients with 
psychosis, often already at illness onset (Hepgul et al., 2012; Pillinger et al., 2017b; Russell et al., 
2015). The combination of overweight, dyslipidaemia, hyperglycaemia and peripheral immune 
activation can lead to severe cardiovascular diseases, like metabolic syndrome, and to increased 
mortality in patients with psychosis (Leonard et al., 2012; Ringen et al., 2014). However, the 
consequences of this abnormal metabolic-inflammatory state for the psychiatric/mental health 
clinical outcome in patients at the onset of psychosis remain undetermined.  
Recent evidence from our group has shown that increased baseline peripheral inflammatory 
markers, such as interleukin (IL)-6, predict poor treatment response at 3-month follow-up in patients 
with first episode psychosis (FEP) (Mondelli et al., 2015). Similarly, metabolic abnormalities in 
patients with bipolar disorder have been reported to be associated with worse psychiatric clinical 
outcome, including higher number of relapses, hospitalizations and more impaired cognitive 
functioning (Bai et al., 2016; Calkin et al., 2009; Fagiolini et al., 2003). Some emerging evidence on 
the effects of inflammation and metabolic abnormalities on the brain can possibly explain this 
association. For example, treatment with IL-1β, a pro-inflammatory cytokine shown to be increased 
in patients with depression or with schizophrenia, decreases neurogenesis in human hippocampal 
progenitor cells (Zunszain et al., 2012). Further evidence of the effect of metabolism on the brain 
comes from resting-state studies. A study from Doucet and colleagues (2018) investigated the 
correlation between BMI and the functional organization of resting-state brain networks, such as the 
default mode network (DMN), and the Sensory Motor Network (SMN). They found a positive 
correlation between BMI and connectivity between the DMN, the SMN and other cerebral networks. 
Such increased integration between networks suggests an increase of sensory driven behavior in 
subjects with higher BMI (Doucet et al., 2018). More interestingly, FEP patients show similar 
connectivity alterations. Resting-state studies have found that the early stage of schizophrenia is 
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associated with increased connectivity between fronto-parietal networks involved in the control of 
cognitive and sensory functions (Anhoj et al., 2018). 
Finally, obesity and overweight are associated with brain structural abnormalities (frontal and 
temporal grey matter atrophy and reduced integrity of white matter in the corpus callosum) and poor 
cognitive and functional outcomes, typically present in FEP (Minichino et al., 2017). 
Growing evidence suggests increased levels of peripheral immune markers in patients at the onset 
of psychosis (Di Nicola et al., 2013; Hepgul et al., 2012; Mondelli et al., 2015; Zajkowska and 
Mondelli, 2014), and the potential for biomarkers of inflammation as predictors of long-term illness 
course (Mondelli et al., 2015). Similarly, levels of the acute phase inflammatory marker C-reactive 
protein (CRP) have been found moderately increased in patients with schizophrenia (Wang et al., 
2017) and resulted to be correlated with the severity of illness and with the presence of relapses 
(Orsolini et al., 2018). Furthermore, in both chronic schizophrenia and at the onset of psychosis, 
CRP blood levels have been correlated with cognitive and negative symptoms severity (Baumeister 
et al., 2014). Despite such evidence, longitudinal studies investigating CRP as a predictor of clinical 
outcome at the onset of psychosis are currently lacking. 
A further aspect to consider is that, due to the relationship between the immune and the metabolic 
system, high levels of peripheral inflammation are generally associated with metabolic abnormalities 
in both the general population and in FEP patients (Russell et al., 2015) (Petrikis et al., 2015; Pillinger 
et al., 2017a; Pillinger et al., 2017b; S et al., 2013). More interestingly, weight gain, increased visceral 
fat and impaired glucose metabolism have been detected also in drug naïve patients (Correll et al., 
2014), with altered insulin signaling being present also in unaffected siblings (Chouinard et al., 2018). 
This suggests these abnormalities to be partly independent of treatment exposure and rather to be 
linked to innate mechanisms of psychiatric illness, including a chronic inflammation state.  
All this evidence supports the relevance of considering an overall metabolic-inflammatory status 
when looking for biomarkers of clinical outcomes of psychosis. No study so far has tested the impact 
of the combination of inflammation-weight gain-metabolic abnormalities on the clinical outcome of 
FEP patients. Based on this evidence, this study aimed to investigate whether, in a sample of FEP 
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patients, inflammation and metabolic status could be considered together as part of an overall 
inflammatory-metabolic factor associated with clinical symptoms at baseline and at 1-year follow-up 
clinical outcome. There is a compelling body of evidence on the association between inflammation 
and BMI and adiposity. In fact, obese individuals present higher circulating levels of CRP (Firdous 
2014); in particular, it is now acknowledged that adipose tissue can contribute to increased peripheral 
inflammation due to the increased release of cytokines from adipocytes and infiltrated macrophages 
(Wensveen et al., 2015).  
As a consequence, we hypothesized that a single factor representing a latent metabolic process 
variable between individuals would express a linear combination of baseline inflammation, BMI 
and/or adiposity and that it could be positively associated with symptoms severity at baseline and 
with 1-year follow-up symptoms severity and treatment response.  
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2. Materials and Methods 
This is a naturalistic longitudinal study in which FEP patients were assessed at baseline (i.e., as 
soon as possible and within 3 months after the first contact with psychiatric services) and then were 
followed-up prospectively for their clinical outcome at 1 year. 
 
     2.1 Sample and study design 
First Episode Psychosis Patients 
Fifty-one first episode psychosis patients were recruited in South-East London as part of the Physical 
health and substance Use Measures in first onset Psychosis (PUMP) and Genetics and Psychosis 
(GAP) studies. The recruitment strategy was based on contacting inpatient and outpatient units of 
the South London and Maudsley (SLAM) NHS Foundation Trust, interviewing staff and reviewing 
clinical notes, and approaching all subjects aged 18–65 who presented for the first time to these 
services for a functional psychotic illness. Patients not fluent in English, with organic psychosis, 
learning disabilities, mental retardation, and physical comorbidities affecting the immune system 
(acute and chronic infections, auto-immune disorders, diabetes and cardiovascular disorders) were 
excluded from the study. Two patients were not included as they had an acute infection and a history 
of chronic inflammation due to an autoimmune disorder, respectively; seven patients with diabetes, 
of which six were on insulin treatment, were also excluded. The final sample was of 42 FEP patients. 
All patients were assessed as soon as possible after their first contact with psychiatric services, and 
not later than 3 months from the first contact. After 1 year, a clinical follow-up was completed on all 
patients to establish treatment response and illness course. The study was approved by the local 
Research Ethics Committee, in accordance with the code of ethics of the World Medical Association, 
and written informed consent was obtained from all participants.  
At the time of the first assessment, 20 patients were taking olanzapine, 13 were taking risperidone, 
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 8 
4 were taking quetiapine, 3 were taking aripiprazole, 1 was taking haloperidol and 1 was taking 
zuclopenthixole. Total duration of treatment from baseline (T1) to follow-up (T2) was calculated, as 
well as total treatment duration at T1 and the main duration of untreated psychosis. Unfortunately, 
information about the main duration of untreated psychosis was available for 34 patients only. 
According to published guidelines (Gardner et al., 2010), chlorpromazine equivalents of the 
cumulative dosage of medications at T1 and T2 were calculated.   
Twenty-one patients received a DSM-IV diagnosis of schizophrenia/schizophreniform disorder, 17 
of schizoaffective or affective psychosis and 4 of psychotic disorder not otherwise specified. 
Validation of clinical diagnosis was obtained using the Operational Criteria (OPCRIT+), reviewing 
the case notes in the first month following first contact with services. All diagnoses were performed 
by qualified psychiatrists, subject to comprehensive training and inter-rater reliability testing (κ = 0.9). 
Indication of clinical status and severity of psychotic symptoms were derived both at baseline (T1) 
and at 1-year follow-up (T2), from the Positive and Negative Syndrome Scale (PANSS).  
PANSS total score was calculated at T2 and was used as a measure of clinical outcome at follow-
up. Positive, Negative and Global symptoms PANSS subscales were used to measure symptoms 
domains at follow-up. We also calculated a continuous measure of treatment response, in terms of 
percentage of improvement from baseline. This was estimated as change in PANSS total scores 
from baseline to follow-up, taking into account PANSS total scores and subtracting a score of 30, as 
even individuals without any mental health condition could score 30 in the PANSS. Therefore, as 
described in previous articles (Leucht et al., 2007), we used the following formula: 100 x ((baseline 
PANSS total score-30)- follow-up PANSS total score-30)/baseline PANSS total score-30).  
Healthy controls 
In order to compare T1 metabolic status of our clinical sample with that of general population, 50 
healthy controls (HC) were recruited in South-East London at T1 through advertisement in local 
newspapers, hospitals, and job centres, as well as from existing volunteer databases. Participants 
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not fluent in English, with learning disabilities, mental retardation, any diagnosis of present or past 
mental disorders and physical disorders affecting the immune system (acute and chronic infections, 
auto-immune disorders, diabetes and cardiovascular disorders) were excluded from the study. 
Controls were screened using the Psychosis Screening Questionnaire (Bebbington and Nayani, 
1995). One participant with diabetes, one with a history of cardiovascular disorders and 2 with 
autoimmune disorders were excluded from the study. The final sample size was 46. Socio-
demographic data and metabolic parameters were collected with the same procedure used for 
patients. Unfortunately, data on T1 fasting glucose were not available in healthy controls. 
After testing normality for metabolic variables (see 2.3), for normally distributed ones, namely Hb1Ac, 
Cholesterol and LDL, independent t-tests were used to assess differences between patients and 
controls. Instead, Mann-Whitney U-tests were performed to explore differences in BMI, hsCRP and 
TG. 
   
2.2 Inflammation and metabolic markers 
Weight was measured to the nearest 0.1 kg, wearing minimal clothing, with an analogue floor scale. 
Height was measured to the nearest 5 mm, without shoes and using a measuring tape. BMI was 
then calculated: body weight (kg)/square of height (m2).  
Fasting blood samples were taken in all subjects only at baseline (T1). Although time of collection 
varied for each participant, all samples were taken in the morning. High sensitivity C-reactive protein 
(hsCRP) was used to assess inflammation and analyzed from serum samples using the Cormay 
hsCRP assay (Hepgul et al., 2012), (laboratory reference range: low <0.1 mg/L; average 1.0-3.0 
mg/L; high>3.0 mg/L). Serum total cholesterol and triglycerides (TG) were measured in serum at the 
time of the blood draw using an enzymatic assay. Low-density lipoprotein (LDL) cholesterol was then 
subsequently calculated using the Friedewald equation (see Hepgul et al., 2012). Glycated 
hemoglobin (HbA1c) was measured in plasma at the time of the blood draw using the Premier 
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Hb9210 system, employing principles of boronate affinity and high-performance liquid 
chromatography. Plasma glucose was measured in plasma upon arrival to the lab using the ADVIA 
2400 to analyze a hexokinase assay (intra-assay CV=0.55, inter-assay CV =2.8). Sociodemographic 
characteristics, clinical measures at T1 and T2 and levels of biomarkers of the sample at T1 are 
shown in Table 1.  
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2.3 Data analysis 
Data were analyzed using the Statistical Package for Social Sciences, version 24.0 (SPSS Inc., 
USA). Continuous variables are presented as mean values with their standard deviations in Table 1. 
Boxplots of metabolic biomarkers  were generated to identify possible outliers for each separate 
biomarker. The identified outliers (>1.5 interquartile range) were removed before running the 
statistical analyses if a specific reason for their outlier status was identified, that is, chronic and acute 
diseases affecting inflammation and metabolism. As participants with such comorbidities were all 
removed a priori from the sample, there were no outliers to remove. 
2.3.1 Factor analyses  
Seven metabolic/inflammatory variables (hsCRP, BMI, Hb1Ac, fasting glucose, triglycerides, 
cholesterol and LDL) at baseline were entered into a factor analysis model (Principal Component 
Analysis-PCA) using SPSS, version 24. PCA allows to combine several variables in a smaller 
number of factors: those variables that strongly correlate with each other are gathered in one factor 
accounting for all of them. As variables were measured with different units, and as some of them 
were not normally distributed, a rank based inverse normal transformation with Blom method was 
applied to all of them before entering the model.  
The Kaiser-Meyer-Oklin (KMO) test and the Bartlett spherical test were used as preliminary tests for 
factor analysis. Due to our preliminary hypothesis that inflammation, BMI and/or adiposity could be 
highly correlated with each other and also be positively associated with T1 and T2 symptoms severity 
and with T2 treatment response, we set the number of factors to 3:1 factor expressing relationship 
between inflammation and BMI, 1 factor for lipid profile and 1 factor for glycemic profile. In order to 
choose the best rotation method (oblique or orthogonal), Direct Oblimin rotation was preliminary 
chosen to explore the correlation matrix between factors. The resulting correlation matrix between 
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factor 1 and 3 showed a value above 0.32 (0.327), so we opted for a Direct Oblimin oblique method  
(Corner, 2009). 
Notably, a factoring of these metabolic variables with PCA has never been used previously. 
Moreover, we could not test the same factoring in another sample, to confirm that variables clustered 
in the same way. So, we investigated whether, beside the correlations between variables in these 
specific samples, the same results could be found simply using the mean of metabolic variables z 
scores, grouped according to our hypothesis. This is simply a measure of the deviation of each 
patient from population mean. To test this, we calculated the mean of z scores of hsCRP, BMI and 
TG for factor 1, that of Cholesterol and LDL for factor 2 and that of HbA1c and fasting glucose for 
factor 3. Then, we correlated the resulting factors with T1 and T2 clinical variables.   
In order to control for T2 metabolic variables effect on T2 symptoms, we conducted a PCA and we 
calculated T2 metabolic factors (data were available for 39 patients). Moreover, we calculated BMI, 
hsCRP and TG T1-T2 trajectory of change. We then performed a correlation analysis between T2 
metabolic factors and T2 clinical variables and between BMI, hsCRP and TG trajectory of change 
and T2 clinical variables. 
 
2.3.3 Statistical correlations and regressions between baseline factors and clinical outcome  
Correlation analyses between metabolic factors at T1 and clinical measures at T1 and T2 were 
explored. Then, for those metabolic factors that resulted to be correlated with T2 variables, a linear 
regression analysis was performed to explore whether metabolic factors were associated with T2 
outcome variables [T2 Treatment response, PANSS total score, PANSS negative score, PANSS, 
positive score, PANSS global score].  
Before running regression analyses, we explored the association of T1 and T2 medication, socio-
demographic variables, namely gender, ethnicity and age, with metabolic factors resulting from PCA, 
as well as with T1 and T2 clinical measures. We also controlled for any difference in clinical and 
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metabolic variables between patients prescribed with olanzapine at T1 and those who were on other 
medication. This is because of the well-known ability of olanzapine to affect metabolism (Park et al., 
2013).  
Moreover, as tobacco-smoking, cannabis and alcohol consumption are well-known to act both on 
inflammatory and metabolic conditions (Fond et al., 2017), we tested whether these three variables 
affected metabolic factors and clinical variables. Data on lifetime use (yes-no) of tobacco and alcohol 
were available for 41 FEP and 45 HC, while data on lifetime cannabis use were available for all 
participants (Table 1).   
Pearson’s correlations and linear regressions were performed with bootstrapping method. This is a 
statistical approach that relies on random resampling with replacement (number of resamplings in 
our analyses: 5000) and allows assigning measures of accuracy to sample estimates. As clinical 
variables showed a skewed distribution, bootstrapping allowed performing the statistic test 
eliminating possible confounding effects of variable distribution. Each regression model was also 
corrected for baseline symptoms to test if the association between metabolic factors and follow-up 
clinical variables could be mediated by baseline clinical variables.  
A Bonferroni correction was adopted with α = 0.0125 for correlations between metabolic factors and 
T1 symptomatic domains (0.05/4, as we had 4 dependent variables: three T1 PANSS sub scores 
and T1 PANSS total score); α = 0.01 for linear regressions between T1 metabolic factors and T2 
symptomatic domains (0.05/5 as there were 5 dependent variables: three T2 PANSS sub scores, T2 
PANSS total score and T2 treatment response).  
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      3.  Results 
3.1 FEP vs HC  
HC group was matched with the FEP group for sociodemographic variables (Table 1). The sex rate 
(M/F) was 26/16 in the FEP sample and 22/24 in the sample of HC. Ethnicities in the FEP sample 
were: 12 white British, 8 white Caucasian, 4 Asian, 9 black Caribbean, 8 black African, 1 black other; 
ethnicities in the healthy controls sample were the following: 16 white British, 4 white Caucasian, 3 
mixed race, 3 Asian, 10 black Caribbean, 9 black African, 1 black other). 
FEP showed higher HbA1c (t=2.15, p=0.034), TG (Mann Whitney U=726.5, p=0.045) and BMI (Mann 
Whitney U=700.0 p=0.026) than HC at baseline. There was a trend difference in hsCRP with patients 
showing higher levels of hsCRP compared with controls (Mann Whitney U= 739.5, p=0.057) (See 
Table 1). 
FEP smoked both tobacco (2=6.4, p=0.04) and cannabis (2=4.8, p=0.028) more than HC (Table 
1), while no difference was found in alcohol consumption (see table 1). Interestingly, the majority of 
patients smoked and drunk alcohol (Table 1). 
In the FEP sample, the mean duration of antipsychotic treatment from T1 to T2 was 222.2 ± 161.4 
days, the mean duration of treatment at T1 was 41.4 ± 45.1 days, while the main duration of 
untreated psychosis was 59.76 ± 182.8 days. The cumulative dose of antipsychotic treatment 
received at T1 was 17.2×103 ± 26.4×103 mg, while the cumulative dose of antipsychotic treatment 
at the time of follow-up assessment was 10.5×105 ± 8.8×105 mg. 
3.2 Factor analysis 
The KMO test (0.614) and the Bartlett test (Chi = 110.8, p <0.001) indicated that the correlation 
matrix between metabolic items was adequate for performing a PCA. PCA allowed identifying 3 
factors contributing to 36.9%, 28.8% and 12.6% of the explained variance respectively (cumulative 
variance =79%). Each factor corresponded to a different metabolic domain. Considering metabolic 
items with the highest score within each factor, the hsCRP clustered with triglycerides and BMI in 
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factor 1; cholesterol and LDL clustered together in factor 2 and fasting glucose and HbA1c clustered 
in factor 3 (Table 2). Extraction communalities were all above 0.6. Extraction communalities are 
estimates of the variance in each variable accounted for by the components, so high values of 
communalities mean that the resulting components represent all variables well.   
 
T2 metabolic variables clustered in three factors (KMO test=0.544; Bartlett test: Chi = 79.1, p 
<0.001). Factor loadings were similar to those of T1 metabolic factors. Factor 1 (T2 
hsCRP+T2TG+T2BMI) explained 38,7% of the variance, T2 factor 2 (T2 LDL+T2 Chol) explained 
20% of total variance, and factor 3 (T2 HbA1c+T2 fasting glucose) explained 14.7% of the variance. 
The mean T1-T2 trajectory of change was 1.9 ± 5.7, 1.03 ± 4.2 and -0.05 ± 0.7 for hsCRP, BMI and 
TG respectively. 
 
3.3 Correlation analyses 
Bootstrapped Pearson’s correlation analysis between metabolic factors and clinical measures at T1 
revealed a significant positive association between metabolic factor 1 and T1 PANSS negative score 
(r=0.354, p=0.021). When correlation between metabolic factors and T2 clinical measures were 
explored, we found that factor 1 positively correlated with T2 PANSS total score (r=0.499, p=0.001), 
T2 PANSS positive score (r=0.356, p=0.021), T2 PANSS negative score (r=0.352, p=0.022,) and T2 
PANSS global score (r=0.516, p<0.001). A significant negative association of both factor 1 and factor 
2 with 1-year T2 treatment response was also found (r=-0.771, p=0.014 and r=-0.327, p=0.034, 
respectively). Correlation analysis between factor 3 and clinical variables at T1 and T2 showed no 
significant results (all p>0.05). 
Confirming that these results persist independently of how the single variables are associated with 
each other in this sample, Pearson’s correlations with bootstrapping using the same metabolic 
factors calculated as means of z scores revealed overlapping results. We confirmed a positive 
association between metabolic factor 1 and T1 PANSS negative score (r=0.368, p=0.017,) and with 
T2 PANSS total score (r=0.496, p=0.001), T2 PANSS positive score (r=0.339, p=0.0278), T2 PANSS 
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negative score (r=0.356, p=0.021) and T2 PANSS global score (r=0.520, p<0.001,). Also, the 
negative association of factor 1 and factor 2 with 1-year T2 treatment response was confirmed (r=-
0.367, p=0.017, and r=-0.336, p=0.030, respectively). Finally, no significant correlations were found 
between factor 3 and clinical variables, again. Gender and ethnicity were not associated with any T1 
and T2 variable (all bootstrapped p>0.05). Although age was not correlated with any clinical variable, 
a significant Pearson’s correlation was found between age and metabolic factor 1 (r=0.371, 
bootstrapped p<0.015). In order to investigate the effect of age, this variable was added to multiple 
regression models. As it was not associated with dependent variables, there was no risk of 
collinearity (this was verified by SPSS collinearity diagnostics).  
While alcohol and tobacco showed no effect on metabolic factors and clinical variables (Mann-
Whitney, all p > 0.05), cannabis use was positively associated with T2 positive symptoms (Mann-
Whitney U=72000, p=0.018). Therefore, we ran an additional regression model including cannabis 
as factor for T2 positive PANSS score.  
Equivalents of chlorpromazine at T1 and T2, total duration of medication at T1 and from T1 to T2 
and duration of untreated psychosis showed no effect on both metabolic factors and T1 and T2 
clinical variables, therefore, these variables were excluded from multiple regression models (all 
bootstrapped p>0.05). Patients on olanzapine resulted to have higher values of metabolic factor 1 
(t=-2.4, p=0.02). So, after running all regression models, we tried to add olanzapine treatment as a 
variable to test whether this significantly affected results. 
Finally, when we explored correlation between T2 metabolic factors and T2 clinical variables, we 
found a significant association of T2 metabolic factor 1 with T2 PANSS negative scores (r=0.407, 
p=0.015) and T2 total PANSS (R=0.355, P=0.036), but not with other symptoms categories. 
Similarly, we found that only hsCRP trajectory of change (but not BMI) correlated with T2 PANSS 
negative score (r=0.432, p=0.010). This was probably driven by the association between hsCrp and 
T2 PANSS negative score (r=0.399, p=0.018). 
3.4 Regression analyses with Metabolic factor 1 (hsCRP, TG, BMI) corrected for age  
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The following regression analysis, corrected for age, confirmed that metabolic factor 1 predicted T2 
global PANSS scores (R2=0.350, bootstrapped p<0.001, See Table 3). T1 global scores were not 
added to the model as they were not correlated with T2 global symptoms scores (Pearson’s 
bootstrapped correlation: r=0.111, p=0.480).  
Metabolic factor 1 alone also predicted T2 PANSS total score (R2=0.249, p=0.001), T2 PANSS 
positive score (R2=0.127, p=0.009) and T2 PANSS negative score (R2=0.124, p=0.007). When these 
models were corrected for T1 symptoms scores, metabolic factor 1 was still predictive of T2 PANSS 
total score (total R2=0.380, bootstrapped p=0.001, see multiple regression model in Table 4).
When the association with T2 positive symptoms severity was explored, metabolic factor 1 showed 
a substantial contribution to the model,  surviving correction for T1 positive symptoms scores and for 
cannabis use (total R2=0.415, metabolic factor 1 bootstrapped p=0.004, =0.616 vs T1 symptoms 
bootstrapped p=0.057, =0.187 and cannabis use bootstrapped p=0.041, =-0.121, Table 5). 
Finally, metabolic factor 1 contribution to the predictive model of T2 negative symptoms did not 
survive correction for multiple comparisons (factor 1 bootstrapped p=0.031, =0.259 vs T1 negative 
symptoms score bootstrapped p=0.083, =0.351) (Table 6).  
 
Metabolic factor 1 (hsCRP, TC, BMI) and 2 (Cholesterol and LDL) and Treatment Response, 
corrected for age. 
Regression analysis revealed that, when including both metabolic factor 1 and 2 into the same 
model, metabolic factor 1 was more predictive of T2 treatment response (total R2=0.274; factor 1 
bootstrapped p=0.007 vs factor 2 bootstrapped p=0.037, Table 7). Notably, after adding olanzapine 
treatment as a variable in all regression models, metabolic factor 1 still predicted clinical variables at 
T2 (PANSS T2 global score: p=0.001, =0.675; PANSS T2 Total score: p=0.002, =0.616; PANSS 
T2 positive score: p=0.005, =0.450; PANSS T2 negative score: p=0.018, =0.350; Treatment 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Nettis et al. 
 
 18 
response: p=0.010, =-0.472), suggesting that the effect was not confounded by the effect of 
olanzapine treatment. 
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Discussion 
In this longitudinal study in first episode psychosis patients, we found that those with worse 
inflammatory-metabolic status at baseline, defined as higher levels of hsCRP, BMI and triglycerides, 
had worse clinical outcome at 1-year follow-up as demonstrated by the presence of higher PANSS 
scores and reduced rate of treatment response at 1-year follow-up. 
 The baseline levels of metabolic and inflammatory markers of our patients reflected  and confirmed 
the presence of subtle metabolic/inflammatory abnormalities in the early stages of psychosis, where 
higher levels of BMI, CRP and triglycerides have been already previously described (Hepgul et al., 
2012; Misiak et al., 2017; Pillinger et al., 2017b). 
We would have expected a gender-driven difference in terms of CRP levels in the FEP sample. 
Previous studies exploring relationship between C-reactive protein and psychiatric disorders have 
found the correlation between CRP and depressive symptoms to be present only in depressed men 
(Tayefi et al., 2017) (Vetter et al., 2013), who showed higher CRP values than women. By contrast, 
a study on 88 patients with schizophrenia (40% males) found that higher hsCRP levels in patients 
were associated with female gender, (Joseph et al., 2015).  Moreover, another study on 485 patients 
with schizophrenia (50% males) from Wysokinski and colleagues found that the rate of patients 
having CRP above 3 mg/L (with higher risk of cardiovascular problem) was higher in women 
(Wysokinski et al., 2015). 
The reason we did not find a difference in CRP similar to that of studies on schizophrenia may be 
attributed to the smaller sample size, to the different sex ratio and to the larger diagnostic spectrum 
of our sample, including patients with schizophrenia, schizoaffective disorder and affective 
psychosis.   
The factor analysis showed that the inflammatory marker CRP clustered into a factor with BMI and 
triglycerides at baseline, as we expected and as confirmed by the alternative method with z-scores 
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mean.  This is in line with findings in the general population  (Ellulu et al., 2017) and highlights a 
close association between inflammation, body weight and eating habits (as triglycerides levels are 
mainly influenced by diet) in FEP patients. Interestingly, baseline triglycerides have been found 
associated with later symptom severity and poor functioning in patients with schizophrenia in a 5-
year follow-up longitudinal study (Solberg et al., 2016). This seems to support the role of triglycerides 
levels as potential predictor of clinical state together with inflammation. Furthermore, this evidence 
suggests that FEP patients could benefit from a dietary education aiming to reduce triglycerides 
levels. For example, it has been shown that a controlled quality and quantity of food intake, low 
alcohol consumption (AbouRjaili et al., 2010) and a high-omega-3 fatty acids diet (Shearer et al., 
2012) are able to significantly reduce triglycerides levels in the general population. 
Factor 1 was associated with baseline PANSS negative symptoms. Although this result (p=0.021) 
did not survive correction for multiple comparisons (α = 0.0125), it is consistent with previous studies 
showing higher CRP levels in patients with negative symptoms. This result is also consistent with 
increased weight gain in the same category of patients, as they typically show sedentary life and 
physical inactivity. Finally, this should be taken into account when interpreting results on factor 1 
ability to predict T2 negative symptoms (which did not survive correction as well), as collinearity 
between factor 1 and T1 negative symptoms score affected the model. Furthermore, also results 
from correlations between T2 metabolic factors and T2 clinical variables proved that the current 
overall metabolic-inflammatory status is associated with current negative symptoms, but not with 
other symptoms clusters and with treatment response. Hence, the ability of baseline metabolic 
factors to predict later positive symptoms, treatment response and general psychopathology offer 
an important opportunity of early intervention in these patients.  
The most interesting and novel finding is the role of factor 1 in predicting PANSS positive score, 
PANSS global score, PANSS total score and treatment response rate at 1-year follow-up. This could 
possibly suggest an effect of abnormal metabolic and inflammatory status on the brain. A recent 
study has highlighted that weight gain is associated with brain structural abnormalities such as 
reduced grey matter integrity in the temporal lobe (Minichino et al., 2017). Interestingly, the same 
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brain region has been implicated in the genesis of positive symptoms of psychosis (Fusar-Poli et al., 
2012) and grey matter reduction of the superior temporal gyrus has been found during transition to 
psychosis  (Takahashi et al., 2009). More interestingly, in our sample a predictive model of positive 
symptoms severity included the metabolic-inflammatory status together with cannabis use. There is 
vast evidence of the association between cannabis consumption and the development of 
schizophrenia (Arseneault et al., 2004). However, in light of our results, future studies should 
investigate the interaction between inflammation, metabolism and cannabis use and its effect on 
positive dimension of schizophrenia.  
Metabolic factor 1 implication with PANSS global scale may be attributed to the well-known 
relationship between inflammation and cognitive-affective symptoms (Baumeister et al., 2014). 
Peripheral inflammation may affect the brain, possibly through cytokines passing the blood brain 
barrier and triggering microglia activation (Cattaneo et al., 2015) and ultimately affecting synaptic 
pruning and brain function and connectivity (Cannon, 2016). Factor 1 was also predictive of follow-
up treatment response and this suggests that new strategies of intervention may target the 
inflammatory and metabolic status at early stages of psychosis in order to reduce possible effects of 
abnormal metabolic-inflammatory status on the brain. Although factor 2 was less predictive of 
treatment response, the role of diet-unrelated lipids such as LDL and total cholesterol should be 
more fully investigated in future studies. 
Finally, the cumulative dose of antipsychotics, in terms of baseline and follow-up chlorpromazine 
equivalents, had no effect on metabolic and clinical variables.  One possible explanation may be that 
treatment response and symptoms severity in this specific sample were not correlated with 
antipsychotics dosage. Also, olanzapine treatment, known to affect metabolism, did not affect our 
results significantly. This suggests that a latent metabolic factor, linking inflammation and metabolic 
status and possibly independent from medication, may contribute to the pathophysiology of 
psychosis. 
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The identification of a key predictive factor including interdependent immune and metabolic variables 
in FEP, supports the potential for evaluating a number of strategies of early intervention, including 
physical exercise, diet monitoring and anti-inflammatory treatment for patients with a specifically 
abnormal metabolic-inflammatory status. Lifestyle interventions and a more careful choice of type 
and timing of antipsychotic prescription would possibly help a better control of the 
metabolic/inflammatory status and contribute to better clinical outcomes. Indeed, FEP patients may 
not only benefit from a dietary education, but also from physical exercise, that could help preventing 
weight gain. In fact, a study from Gates and colleagues (2015) pointed out that prevention of weight 
gain is much more achievable and long-lasting than weight loss in FEP patients. The same authors 
highlight the importance of early intervention for smoking cessation, that is also likely to result in 
improved health outcomes and, more specifically, in reduced inflammation. Although patients with a 
first episode of psychosis are six times more likely to be current tobacco users than age-matched 
and sex-matched healthy controls (as confirmed by our results), people with schizophrenia who quit 
early are likely to maintain their smoking cessation status (Gates et al., 2015). 
As later interventions, anti-inflammatory medications (Mondelli et al., 2017) may reverse microglia 
activation and improve functioning and cognition. 
We need to acknowledge few limitations of this study. First, the sample size of our FEP patients 
was relatively small and our factor analysis needs to be replicated in a larger sample. Second, we 
did not have specific measures of insulin resistance, adiposity or adipose distribution that could 
possibly further refine the characterization of a metabolic-inflammatory factor; and these factors 
should be explored in future studies.  Finally, 17 patients were on antidepressants, but we were not 
able to control for the effect of depressive symptoms and anti-depressant medication on patients’ 
metabolic-inflammatory status. This is something that future studies should try to address. AC
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 Conclusions 
In conclusion, our findings further confirm a close interdependency between inflammation and 
metabolism in patients at their onset of psychosis as already partly suggested by our previous 
studies (Hepgul et al., 2012; Russell et al., 2015). Our data also support the hypothesis that these 
physical health factors may play a role in the clinical course of psychosis and that the metabolic-
inflammatory status should be taken into account in early intervention approaches for psychosis. 
Such approaches may include a dietary education, physical exercise and early intervention for 
smoking cessation. 
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Table 1 Sociodemographic characteristics, baseline levels of biomarkers and clinical 
variables indicated as mean ± standard deviation. Significant tests (p<0.05) are in bold. 
1 High sensitivity C reactive protein   
2 Glycated hemoglobine 
3 Triglycerides 
4 Total cholesterol 
5 Low Density Lipoprotein cholesterol 
6 Positive and Negative Syndrome Scale 
 
 FEP (=42) HC (n=46) Test and significance 
Age (y) 30.3±9.8 28.7±9.2 U=859.5, p=0.373 
Gender  (M/F) 26/17 22/28 2=2.5, p=0.113 
Ethnicity (White/Black/Asian/Mixed) 20/18/4 20/20/3/3 2=8.7, p=0.560 
T1 1hsCRP (mg/L) 2.3±3.2 1.5±1.9 U=739.5, p=0.057 
T1 2HbA1c (%) 5.3±0.4 5.1±0.3 t=2.15, p=0.034 
T1 Fasting glucose (mmol/L) 4.7±0.4 - - 
T1 3Triglycerides (mg/dl) 1.4±0.7 1.1±0.5 U=726.5, p=0.045 
T1 4Cholesterol (mg/dl) 4.9±0.7 5.1±1.1 t=1.2, p=0.237 
T1 5LDL (mg/dl) 2.8±0.6 3.05±0.90 t=1.3, p=0.210 
T1 BMI kg/m2 26.9±5.2 24.4±3.4 U=700.0, p=0.026 
Tobacco lifetime use (yes/no) 
 
34/7 
(n=41) 
26/19 
(n=45) 
2=6.4, p=0.04 
Alcohol lifetime use (yes/no) 37/4 
(n=41) 
43/2 
(n=45) 
2=0.93, p=0.63 
Cannabis lifetime use (yes/no 33/9 26/20 2=4.8, p=0.028 
T1 6PANSS total score 
T2  PANSS total score 
59.4±12.3 
50.1±15.2 
- - 
T1 PANSS positive score 
T2 PANSS positive score 
12.8±4.9 
11.9±5.5 
- - 
T1 PANSS negative score 
T2 PANSS negative score 
15.1±5.9 
13.1±5.9 
- - 
T1 PANSS global score 
T2 PANSS global score 
28.7±5.9 
24.1±6.9 
- - 
Treatment response 27.5±56.3 - - AC
CE
PT
ED
 M
AN
US
CR
IPT
Nettis et al. 
 
 30 
Table 2 Metabolic variables Principal component analysis Structure after Direct Oblimin rotation. 
The bold values indicate the items highest scores for each factor. 
Structure Matrix 
 Components 
 1 
variance explained: 36.9% 
eigenvalue: 2.5 
2 
variance explained: 28.8% 
eigenvalue: 2.0 
3 
variance explained:12.6% 
eigenvalue: 0.8 
Normal score of T1 1hsCRP 0.829 -0.010 0.463 
Normal score of T1 2HbA1c 0.228 -0.076 0.915 
Normal Score of T1 fasting glucose 0.442 -0.262 0.820 
Normal score of T1 3TG 0.744 0.433 0.296 
Normal score of T1 4Cholesterol 0.209 0.940 -0.099 
Normal score of T1 5LDL 0.121 0.937 -0.186 
Normal score of T1 BMI 0.831 0.156 0.149 
Extraction method: Principal component analysis 
Rotation method: Oblimin with Kaiser Normalization 
 
1 High sensitivity C reactive protein   
2 Glycated hemoglobine  
3 Triglycerides 
4Total cholesterol 
5 Low Density Lipoprotein cholesterol 
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Table 3 Linear regression analysis with bootstrapping with independent variable: metabolic 
factor 1. Dependent variable: T2 global PANSS score. Covariate: age. 
 
1Positive and Negative Syndrome Scale 
2 High sensitivity C reactive protein 
3Triglycerides 
 
 
Table 4 Linear regression analysis with bootstrapping with independent variables: metabolic 
factor 1 and T1 total PANSS score. Dependent variable: T2 total PANSS score. Covariate: age. 
The linear model illustrates the single contribution of each independent variable in predicting the 
dependent one. In the multiple model independent variables are considered together. 
T2 1PANSS total score 
Regression model Variable(s) included  Predictors (Bootstrapping) 
                                                    R    R2 p-value  B(SE)        p-value 
Linear 
T1 Metabolic factor 1 
(2hsCRP+3TG+BMI) 
0.499 0.249 0.001 T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
 7.5(1.6)  0.499          <0.001 
T1 PANSS total score 0.308 0.095 0.047 T1 PANSS total score   0.4(0.2)  0.308          0.022 
Forced entry, multiple 
T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
T1 PANSS total score  
Age 
 
0.617 0.380 <0.001 T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
T1 PANSS total score  
 
 
 8.8(2.0)          
 
 0.2(0.2) 
 -0.5(0.2) 
  
 0.581          0.001     
 
 0.183          0.167 
-0.313          0.032 
          
1Positive and Negative Syndrome Scale 
2 High sensitivity C reactive protein 
3Triglycerides 
 
  
 
 
T2 1PANSS global score 
Regression model Variable(s) included  Predictors (Bootstrapping) 
                                                    R    R2 p-value  B(SE)          p-value 
Forced entry, multiple        
T1 Metabolic factor 1 
(2hsCRP+3TG+BMI) 
Age 
0.592 0.350 <0.001 T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
Age 
 
-4.4(0.9)          
 
-0.2(0.1) 
 
   0.632          
 
   -0.312   
     
 <0.001 
  
     0.750 
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Table 5 Linear regression analysis with bootstrapping with independent variables: metabolic 
factor 1 and T1 PANSS positive score. Dependent variable: T2 positive PANSS score. 
Covariates: age, cannabis lifetime use. The linear model illustrates the single contribution of each 
independent variable in predicting the dependent one. In the multiple model independent variables 
are considered together.  
T2 1PANSS positive score 
Regression model Variable(s) included  Predictors (Bootstrapping) 
                                                    R    R2 p-value  B(SE)        p-value 
Linear 
T1 Metabolic factor 1 
(2hsCRP+3TG+BMI) 
0.356 0.127 0.021 T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
 1.9(0.6)  0.356          0.009 
T1 PANSS positive score 
 
Cannabis lifetime use 
(yes/no) 
0.401 
 
0.347 
0.161 
 
0.121 
0.009 
 
0.024 
T1 PANSS positive score 
 
Cannabis lifetime use 
(yes/no) 
  0.4(0.2) 
 
4.6(1.02) 
 0.401  
 
 0.307        
    0.024 
 
  0.003 
Forced entry, multiple 
T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
T1 PANSS positive score  
Age 
Cannabis lifetime use 
(yes/no) 
0.644 0.415 <0.001 T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
T1 PANSS positive score  
Age 
Cannabis (yes/no) 
 9.3(1.2)          
 
 0.2(0.2) 
 -0.5(0.3) 
-3.6(4.1)                
 0.616          0.004   
 
 0.187          0.057 
-0.182          0.049 
-0.121.         0.041 
 
1Positive and Negative Syndrome Scale 
2 High sensitivity C reactive protein   
3Triglycerides 
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Table 6 Linear regression analysis with bootstrapping with independent variables: metabolic 
factor 1 and T1 PANSS negative score. Dependent variable: T2 PANSS negative score. 
Covariate: age. The linear model illustrates the single contribution of each independent variable in 
predicting the dependent one. In the multiple model independent variables are considered together. 
 
1Positive and Negative Syndrome Scale 
2 High sensitivity C reactive protein  
3Triglycerides 
 
 
 
T2 1PANSS negative score 
Regression model Variable(s) included  Predictors (Bootstrapping) 
                                                    R    R
2 p-value  B(SE)   p-value 
Linear 
T1 Metabolic factor 1 
(2hsCRP+3TG+BMI) 
0.352 0.124 0.022 T1 Metabolic factor 1 
(CRP+TG+BMI) 
 2.1(0.6) 0.352         0.007 
T1 PANSS negative score 0.423 0.179 0.005 T1 PANSS negative score 
 
 0.4(0.2) 0.423          0.012 
Forced entry, multiple 
T1 Metabolic factor 1 
(CRP+TG+BMI) 
T1 PANSS negative score  
Age  
 
0.495 0.245 0.013 T1 Metabolic factor 1 
(CRP+TG+BMI) 
T1 PANSS negative score  
Age 
 
 
 1.7(0.8)          
 
 0.3(0.2) 
-0.06(0.1) 
 
 
 0.295        0.031         
 
 0.351        0.083 
-0.351        0.199 
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Table 7. Linear regression analysis with bootstrapping with independent variables: metabolic 
factor 1 and metabolic factor 2. Dependent variable: T2 treatment response. Covariate: age. 
The linear model illustrates the single contribution of each independent variable in predicting the 
dependent one. In the multiple model independent variables are considered together. 
 
Treatment Response 
Regression model Variable(s) included  Predictors (Bootstrapping) 
                                                    R     R2 p-value  B(SE)   p-value 
Linear 
T1 Metabolic factor 1 
(1hsCRP+2TG+BMI) 
0.377 0.142 0.014 T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
-21.2(7.9) -0.38          0.011 
T1 Metabolic factor 2 
(3Chol+4LDL) 
0.327 0.107 0.034 T1 Metabolic factor 2 
(Chol+LDL) 
-18.4(7.2) -0.33       0.015 
Forced entry, multiple 
T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
T1 Metabolic factor 2 
(Chol+LDL) 
Age 
 
0.523 0.274 0.006 T1 Metabolic factor 1 
(hsCRP+TG+BMI) 
T1 Metabolic factor 2 
(Chol+LDL) 
Age 
 
 -24.3(8.7) 
 
 -14.3(6.8) 
 
   1.5(0.9)     
    
-0.432 
 
-0.255 
 
 0.264  
  
                 
 0.007 
 
 0.037 
 
 0.072  
                
1 High sensitivity C reactive protein   
2 Triglycerides 
3 Total cholesterol 
4 Low Density Lipoprotein cholesterol
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